TY - JOUR
T1 - Acute Myeloid Leukemia, Version 2.2021 Featured Updates to the NCCN Guidelines
AU - Pollyea, Daniel A.
AU - Bixby, Dale
AU - Perl, Alexander
AU - Bhatt, Vijaya Raj
AU - Altman, Jessica K.
AU - Appelbaum, Frederick R.
AU - Lima, Marcos De
AU - Fathi, Amir T.
AU - Foran, James M.
AU - Gojo, Ivana
AU - Hall, Aric C.
AU - Jacoby, Meagan
AU - Lancet, Jeffrey
AU - Mannis, Gabriel
AU - Marcucci, Guido
AU - Martin, Michael G.
AU - Mims, Alice
AU - Neff, Jadee
AU - Nejati, Reza
AU - Olin, Rebecca
AU - Percival, Mary Elizabeth
AU - Prebet, Thomas
AU - Przespolewski, Amanda
AU - Rao, Dinesh
AU - Ravandi-Kashani, Farhad
AU - Shami, Paul J.
AU - Stone, Richard M.
AU - Strickland, Stephen A.
AU - Sweet, Kendra
AU - Vachhani, Pankit
AU - Wieduwilt, Matthew
AU - Gregory, Kristina M.
AU - Ogba, Ndiya
AU - Tallman, Martin S.
N1 - Funding Information:
This activity is supported by educational grants from Agios Pharmaceuticals; AstraZeneca; Clovis Oncology, Inc.; Daiichi Sankyo; Eisai; Epizyme Inc.; Novartis; and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. This activity is supported by an independent medical education grant from Bristol-Myers Squibb, and Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme. This activity is supported by an independent medical educational grant from Mylan Inc. This activity is supported by a medical education grant from Karyopharm Therapeutics.
Funding Information:
Vijaya Raj Bhatt, MBBS, Panel Member, has disclosed that he receives grant/research support from AbbVie, Inc., Incyte Corporation, Jazz Pharmaceuticals Inc., Tolero, and Pfizer Inc.; consulting fees from AbbVie, Inc., Genentech, Inc., Incyte Corporation, Omeros, Rigel, and Takeda Pharmaceuticals North America, Inc.; and other financial benefit from Oncoceutics.
Publisher Copyright:
© JNCCN-Journal of the National Comprehensive Cancer Network.
PY - 2021/1
Y1 - 2021/1
N2 - The NCCN Guidelines for Acute Myeloid Leukemia (AML) provide recommendations for the diagnosis and treatment of adults with AML based on clinical trials that have led to significant improvements in treatment, or have yielded new information regarding factors with prognostic importance, and are intended to aid physicians with clinical decision-making. These NCCN Guidelines Insights focus on recent select updates to the NCCN Guidelines, including familial genetic alterations in AML, postinduction or postremission treatment strategies in low-risk acute promyelocytic leukemia or favorable-risk AML, principles surrounding the use of venetoclax-based therapies, and considerations for patients who prefer not to receive blood transfusions during treatment.
AB - The NCCN Guidelines for Acute Myeloid Leukemia (AML) provide recommendations for the diagnosis and treatment of adults with AML based on clinical trials that have led to significant improvements in treatment, or have yielded new information regarding factors with prognostic importance, and are intended to aid physicians with clinical decision-making. These NCCN Guidelines Insights focus on recent select updates to the NCCN Guidelines, including familial genetic alterations in AML, postinduction or postremission treatment strategies in low-risk acute promyelocytic leukemia or favorable-risk AML, principles surrounding the use of venetoclax-based therapies, and considerations for patients who prefer not to receive blood transfusions during treatment.
UR - http://www.scopus.com/inward/record.url?scp=85099750763&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85099750763&partnerID=8YFLogxK
U2 - 10.6004/JNCCN.2021.0002
DO - 10.6004/JNCCN.2021.0002
M3 - Article
C2 - 33406488
AN - SCOPUS:85099750763
VL - 19
SP - 16
EP - 27
JO - Journal of the National Comprehensive Cancer Network : JNCCN
JF - Journal of the National Comprehensive Cancer Network : JNCCN
SN - 1540-1405
IS - 1
ER -